You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFlurazepam
Accession NumberDB00690  (APRD00983)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA benzodiazepine derivative used mainly as a hypnotic. [PubChem]
Structure
Thumb
Synonyms
Flurazepam
Flurazépam
Flurazepamum
Insumin
External Identifiers
  • ID 480
  • Ro 5-6901
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bio-flurazepamCapsule30 mgOralBiomed Pharma2004-04-23Not applicableCanada
Bio-flurazepamCapsule15 mgOralBiomed Pharma2004-04-23Not applicableCanada
DalmaneCapsule30 mgOralValeant Canada Lp/valeant Canada s.e.c.1971-12-312016-07-08Canada
DalmaneCapsule15 mgOralValeant Canada Lp/valeant Canada s.e.c.1971-12-312016-07-08Canada
FlurazepamCapsule15 mgOralAa Pharma Inc1982-12-31Not applicableCanada
FlurazepamCapsule30 mgOralAa Pharma Inc1982-12-31Not applicableCanada
Flurazepam 15Capsule15 mgOralPro Doc Limitee1982-12-31Not applicableCanada
Flurazepam 15mg CapsuleCapsule15 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Flurazepam 30Capsule30 mgOralPro Doc Limitee1982-12-31Not applicableCanada
Flurazepam 30mg CapsuleCapsule30 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Novo-flupam Cap 15mgCapsule15 mgOralNovopharm Limited1980-12-312000-08-25Canada
Novo-flupam Cap 30mgCapsule30 mgOralNovopharm Limited1980-12-312001-03-30Canada
PMS-flurazepam Cap 15mgCapsule15 mgOralPharmascience Inc1986-12-31Not applicableCanada
PMS-flurazepam Cap 30mgCapsule30 mgOralPharmascience Inc1986-12-311996-09-10Canada
Riva-flurazepam 15mg CapsulesCapsule15 mgOralLaboratoire Riva Inc1999-11-262003-07-28Canada
Riva-flurazepam 30mg CapsulesCapsule30 mgOralLaboratoire Riva Inc1999-11-262003-07-28Canada
Som-pamCapsule15 mgOralBiomed Pharma1981-12-31Not applicableCanada
Som-pamCapsule30 mgOralBiomed Pharma1981-12-31Not applicableCanada
Somnol 15mgTablet15 mgOralAxxess Pharma Inc.1981-12-312011-07-22Canada
Somnol 30mgTablet30 mgOralAxxess Pharma Inc.1981-12-312011-07-22Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FlurazepamCapsule30 mg/1OralPreferred Pharmaceuticals, Inc2012-01-27Not applicableUs
FlurazepamCapsule30 mg/1OralWest ward Pharmaceutical Corp1986-12-08Not applicableUs
FlurazepamCapsule15 mg/1OralWest ward Pharmaceutical Corp1986-12-08Not applicableUs
FlurazepamCapsule30 mg/1OralRebel Distributors Corp1986-12-08Not applicableUs
FlurazepamCapsule15 mg/1OralA S Medication Solutions Llc1986-12-08Not applicableUs
FlurazepamCapsule30 mg/1OralGolden State Medical Supply, Inc.1986-12-08Not applicableUs
FlurazepamCapsule30 mg/1OralH.J. Harkins Company, Inc.1986-12-08Not applicableUs
FlurazepamCapsule30 mg/1Oralbryant ranch prepack1986-12-08Not applicableUs
FlurazepamCapsule30 mg/1OralA S Medication Solutions Llc1986-12-08Not applicableUs
Flurazepam HydrochlorideCapsule30 mg/1OralPd Rx Pharmaceuticals, Inc.1985-11-27Not applicableUs
Flurazepam HydrochlorideCapsule15 mg/1OralPhysicians Total Care, Inc.1995-05-08Not applicableUs
Flurazepam HydrochlorideCapsule15 mg/1OralMylan Pharmaceuticals Inc.1985-11-27Not applicableUs
Flurazepam HydrochlorideCapsule30 mg/1OralMylan Pharmaceuticals Inc.1985-11-27Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DalmadormMeda
Dalmadorm mediumMeda
FelisonSIT
FlunoxTeofarma
SompanI.C.N.
ValdormValeas
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Flurazepam Hydrochloride
36105-20-1
Thumb
  • InChI Key: PUGVROXLRUQCAF-UHFFFAOYSA-N
  • Monoisotopic Mass: 423.128046024
  • Average Mass: 424.339
DBSALT000543
Categories
UNIIIHP475989U
CAS number17617-23-1
WeightAverage: 387.878
Monoisotopic: 387.151368285
Chemical FormulaC21H23ClFN3O
InChI KeySAADBVWGJQAEFS-UHFFFAOYSA-N
InChI
InChI=1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3
IUPAC Name
7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
Pharmacology
IndicationFor short-term and intermittent use in patients with recurring insomnia and poor sleeping habits
Structured Indications
PharmacodynamicsFlurazepam, a benzodiazepine derivative, is a hypnotic agent which does not appear to decrease dream time as measured by rapid eye movements (REM). Furthermore, it decreases sleep latency and number of awakenings for a consequent increase in total sleep time.
Mechanism of actionFlurazepam binds to an allosteric site on GABA-A receptors. Binding potentiates the action of GABA on GABA-A receptors by opening the chloride channel within the receptor, causing chloride influx and hyperpolarization.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
potentiator
HumanP14867 details
Gamma-aminobutyric acid receptor subunit alpha-2Proteinyes
potentiator
HumanP47869 details
Gamma-aminobutyric acid receptor subunit alpha-3Proteinyes
potentiator
HumanP34903 details
Gamma-aminobutyric acid receptor subunit alpha-4Proteinyes
potentiator
HumanP48169 details
Gamma-aminobutyric acid receptor subunit alpha-5Proteinyes
potentiator
HumanP31644 details
Gamma-aminobutyric acid receptor subunit alpha-6Proteinyes
potentiator
HumanQ16445 details
Gamma-aminobutyric acid receptor subunit beta-1Proteinyes
potentiator
HumanP18505 details
Gamma-aminobutyric acid receptor subunit beta-2Proteinyes
potentiator
HumanP47870 details
Gamma-aminobutyric acid receptor subunit beta-3Proteinyes
potentiator
HumanP28472 details
Gamma-aminobutyric acid receptor subunit gamma-1Proteinyes
potentiator
HumanQ8N1C3 details
Gamma-aminobutyric acid receptor subunit gamma-2Proteinyes
potentiator
HumanP18507 details
Gamma-aminobutyric acid receptor subunit gamma-3Proteinyes
potentiator
HumanQ99928 details
Gamma-aminobutyric acid receptor subunit deltaProteinyes
potentiator
HumanO14764 details
Gamma-aminobutyric acid receptor subunit epsilonProteinyes
potentiator
HumanP78334 details
Gamma-aminobutyric acid receptor subunit piProteinyes
potentiator
HumanO00591 details
Gamma-aminobutyric acid receptor subunit rho-1Proteinyes
potentiator
HumanP24046 details
Gamma-aminobutyric acid receptor subunit rho-2Proteinyes
potentiator
HumanP28476 details
Gamma-aminobutyric acid receptor subunit rho-3Proteinyes
potentiator
HumanA8MPY1 details
Gamma-aminobutyric acid receptor subunit thetaProteinyes
potentiator
HumanQ9UN88 details
Related Articles
AbsorptionFlurazepam hydrochloride is rapidly (30 minutes) absorbed from the gastrointestinal tract
Volume of distributionNot Available
Protein binding83%
Metabolism

Flurazepam is rapidly metabolized and is excreted primarily in the urine. Both hydroxyethyl flurazepam (the major metabolite) and N-desalkyl flurazepam are active. The N-desalkyl metabolite is slowly excreted in the urine as the conjugated form

SubstrateEnzymesProduct
Flurazepam
Not Available
Hydroxyethyl flurazepamDetails
Flurazepam
Not Available
N-desalkyl flurazepamDetails
Route of eliminationFlurazepam is rapidly metabolized and is excreted primarily in the urine. Less than 1% of the dose is excreted in the urine as N1-desalkyl-flurazepam.
Half lifeThe mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours
ClearanceNot Available
ToxicityComa, confusion, low blood pressure, sleepiness
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Flurazepam is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Flurazepam is combined with 7-Nitroindazole.Experimental
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Flurazepam.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Flurazepam.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Flurazepam.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Flurazepam is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Flurazepam.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Agomelatine.Approved, Investigational
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Flurazepam.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Flurazepam is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Flurazepam.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flurazepam.Approved, Illicit, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Flurazepam.Approved, Investigational
Ambroxol acefyllinateThe therapeutic efficacy of Flurazepam can be decreased when used in combination with Ambroxol acefyllinate.Experimental
AminophyllineThe therapeutic efficacy of Flurazepam can be decreased when used in combination with Aminophylline.Approved
AmiodaroneThe metabolism of Flurazepam can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Flurazepam.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Flurazepam is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Amperozide.Experimental
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Flurazepam.Approved
AprepitantThe serum concentration of Flurazepam can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Flurazepam is combined with Aripiprazole.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Flurazepam.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Asenapine.Approved
AtazanavirThe metabolism of Flurazepam can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Flurazepam.Approved
AtomoxetineThe metabolism of Flurazepam can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Flurazepam.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Azaperone.Vet Approved
AzelastineFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Flurazepam is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Flurazepam is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Flurazepam is combined with Benzyl alcohol.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Flurazepam.Approved, Vet Approved
BexaroteneThe serum concentration of Flurazepam can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Flurazepam can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Flurazepam can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Flurazepam can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Flurazepam.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Flurazepam.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Flurazepam is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Bromazepam.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Flurazepam.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flurazepam.Approved, Investigational
BuprenorphineFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Flurazepam.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flurazepam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Flurazepam is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Flurazepam is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Flurazepam is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flurazepam.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Flurazepam.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Flurazepam.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Flurazepam.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Flurazepam.Approved
CarbamazepineThe metabolism of Flurazepam can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Flurazepam is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Flurazepam.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Carisoprodol.Approved
CeritinibThe serum concentration of Flurazepam can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Flurazepam.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Flurazepam.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorphenamine.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Flurazepam.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorzoxazone.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Flurazepam.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Flurazepam.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Flurazepam.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Flurazepam.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Flurazepam.Approved
ClarithromycinThe metabolism of Flurazepam can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Flurazepam can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Flurazepam is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Flurazepam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Flurazepam is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Flurazepam.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Flurazepam.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Flurazepam.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flurazepam.Approved, Illicit
ClotrimazoleThe metabolism of Flurazepam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Clozapine.Approved
CobicistatThe metabolism of Flurazepam can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Flurazepam.Approved
CocaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Flurazepam.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Flurazepam.Approved
ConivaptanThe serum concentration of Flurazepam can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Flurazepam.Approved
CrizotinibThe metabolism of Flurazepam can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Flurazepam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Flurazepam.Approved
DabrafenibThe serum concentration of Flurazepam can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Flurazepam.Approved
DantroleneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Flurazepam.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flurazepam.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Flurazepam can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Flurazepam can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Flurazepam.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Flurazepam.Approved
DeferasiroxThe serum concentration of Flurazepam can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Flurazepam can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Flurazepam is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Flurazepam can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flurazepam.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flurazepam.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dezocine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Flurazepam.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Flurazepam.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Flurazepam.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Flurazepam.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Flurazepam can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Flurazepam.Illicit
DiltiazemThe metabolism of Flurazepam can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Flurazepam.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Flurazepam.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Flurazepam.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Flurazepam.Approved, Investigational
DoxycyclineThe metabolism of Flurazepam can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Flurazepam is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Illicit
DronedaroneThe metabolism of Flurazepam can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flurazepam.Approved
DyphyllineThe therapeutic efficacy of Flurazepam can be decreased when used in combination with Dyphylline.Approved
EcgonineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Flurazepam is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Flurazepam.Approved
EfavirenzThe serum concentration of Flurazepam can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Flurazepam.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Flurazepam.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Flurazepam is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Flurazepam can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Flurazepam.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Flurazepam.Approved, Investigational
ErythromycinThe metabolism of Flurazepam can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Flurazepam is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Flurazepam can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Flurazepam.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Flurazepam.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Flurazepam.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flurazepam.Approved
EthanolFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flurazepam.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Flurazepam.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Flurazepam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Flurazepam.Approved
EtorphineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Flurazepam can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Flurazepam.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Flurazepam.Approved
EzogabineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Flurazepam.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Flurazepam.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Flurazepam.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Flibanserin.Approved
FluconazoleThe metabolism of Flurazepam can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flurazepam.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Flurazepam.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Flurazepam can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Flurazepam can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Flurazepam can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Flurazepam.Approved
FospropofolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fospropofol.Approved, Illicit
Fusidic AcidThe serum concentration of Flurazepam can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Flurazepam is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Flurazepam is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Flurazepam.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Flurazepam.Approved
GepironeThe risk or severity of adverse effects can be increased when Flurazepam is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Glutethimide.Approved, Illicit
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Flurazepam.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Flurazepam.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Flurazepam.Approved
HalothaneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Flurazepam is combined with Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Flurazepam can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Flurazepam.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flurazepam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Flurazepam.Approved
IdelalisibThe serum concentration of Flurazepam can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Iloperidone.Approved
ImatinibThe metabolism of Flurazepam can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Flurazepam.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Flurazepam.Approved
IndalpineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Flurazepam can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Flurazepam.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Flurazepam.Approved, Investigational
IsavuconazoniumThe metabolism of Flurazepam can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Isoflurane.Approved, Vet Approved
IsradipineThe metabolism of Flurazepam can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Flurazepam can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Flurazepam can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Flurazepam.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Flurazepam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Flurazepam can be decreased when combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Flurazepam.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Flurazepam.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Flurazepam.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Flurazepam.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Flurazepam.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Flurazepam.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Flurazepam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Flurazepam.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Flurazepam.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Flurazepam.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Flurazepam.Approved
LithiumThe risk or severity of adverse effects can be increased when Flurazepam is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Flurazepam is combined with Lofentanil.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Flurazepam.Approved
LopinavirThe metabolism of Flurazepam can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Flurazepam.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Flurazepam.Approved
LovastatinThe metabolism of Flurazepam can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Flurazepam.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Flurazepam is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Flurazepam can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Flurazepam can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Vet Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Flurazepam.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Flurazepam is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flurazepam.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Metaxalone.Approved
MethadoneFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Flurazepam.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Flurazepam.Approved
MethotrimeprazineFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Flurazepam.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Flurazepam.Approved, Investigational
MetyrosineFlurazepam may increase the sedative activities of Metyrosine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Flurazepam.Approved, Illicit
MifepristoneThe serum concentration of Flurazepam can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Flurazepam is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Flurazepam.Approved
MirtazapineFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Flurazepam can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Flurazepam.Approved, Investigational
ModafinilThe serum concentration of Flurazepam can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Molindone.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Flurazepam.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Flurazepam.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Flurazepam.Approved
NafcillinThe serum concentration of Flurazepam can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Flurazepam.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Flurazepam.Approved, Vet Approved
NefazodoneThe metabolism of Flurazepam can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Flurazepam can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Flurazepam can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Flurazepam can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Flurazepam.Approved
NicotineThe metabolism of Flurazepam can be decreased when combined with Nicotine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Flurazepam.Approved
NilotinibThe metabolism of Flurazepam can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Flurazepam.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Flurazepam.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flurazepam.Approved, Investigational
OlaparibThe metabolism of Flurazepam can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Flurazepam.Approved
OndansetronThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Flurazepam is combined with Opium.Approved, Illicit
OrphenadrineFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Flurazepam is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Flurazepam can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Flurazepam is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flurazepam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Flurazepam.Approved, Vet Approved
PalbociclibThe serum concentration of Flurazepam can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Flurazepam.Approved, Investigational
ParaldehydeFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Flurazepam.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flurazepam.Approved, Vet Approved
PentobarbitalThe metabolism of Flurazepam can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved
PerazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Flurazepam is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Flurazepam.Approved
PhenobarbitalThe metabolism of Flurazepam can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Flurazepam.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Flurazepam.Approved
PizotifenThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pizotifen.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Flurazepam.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Flurazepam.Approved
PosaconazoleThe metabolism of Flurazepam can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleFlurazepam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Flurazepam.Approved
PrazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Flurazepam.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Flurazepam.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Flurazepam.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Flurazepam.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Prilocaine.Approved
PrimidoneThe metabolism of Flurazepam can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flurazepam.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Flurazepam.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Flurazepam.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Flurazepam.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Flurazepam.Approved
PSD502The risk or severity of adverse effects can be increased when Flurazepam is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Quazepam.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Flurazepam.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Flurazepam.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Flurazepam.Approved
RacloprideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ramelteon.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Flurazepam.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Flurazepam.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Flurazepam is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flurazepam.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Flurazepam.Approved
RifabutinThe metabolism of Flurazepam can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Flurazepam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Flurazepam can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Flurazepam.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Flurazepam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Flurazepam can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Flurazepam.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Flurazepam.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Romifidine.Vet Approved
RopiniroleFlurazepam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flurazepam.Approved
RotigotineFlurazepam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Flurazepam.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Flurazepam is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Flurazepam is combined with Sage 547.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Flurazepam.Approved, Vet Approved
SaquinavirThe serum concentration of Flurazepam can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flurazepam.Approved, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Flurazepam.Approved
SertindoleThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Flurazepam can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Flurazepam.Approved
SiltuximabThe serum concentration of Flurazepam can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Flurazepam can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Flurazepam.Approved, Investigational
Sodium oxybateFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Flurazepam.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Flurazepam.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Flurazepam.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Flurazepam.Experimental
St. John's WortThe serum concentration of Flurazepam can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Flurazepam can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Flurazepam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flurazepam.Approved
SuvorexantFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Flurazepam.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Flurazepam.Approved
TandospironeThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Flurazepam.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Flurazepam.Approved
TeduglutideThe serum concentration of Flurazepam can be increased when it is combined with Teduglutide.Approved
TelaprevirThe metabolism of Flurazepam can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Flurazepam can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Flurazepam.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Flurazepam.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tetrodotoxin.Investigational
ThalidomideFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Flurazepam can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Flurazepam is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Flurazepam.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Flurazepam.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Flurazepam.Approved
TiclopidineThe metabolism of Flurazepam can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Flurazepam.Approved
TizanidineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Flurazepam can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tolcapone.Approved, Withdrawn
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Flurazepam.Approved
TopiramateThe risk or severity of adverse effects can be increased when Flurazepam is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Flurazepam.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Flurazepam.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Flurazepam.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Flurazepam.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Flurazepam.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flurazepam.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Flurazepam is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Flurazepam.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Flurazepam.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Flurazepam.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Flurazepam.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Flurazepam.Approved
VenlafaxineThe metabolism of Flurazepam can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Flurazepam can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Flurazepam is combined with Vigabatrin.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Flurazepam.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Flurazepam.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Flurazepam.Approved
VoriconazoleThe metabolism of Flurazepam can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Flurazepam can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Flurazepam.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Flurazepam can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zolazepam.Vet Approved
ZolpidemFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.
References
Synthesis Reference

Fryer, R. and Sternbach, L.H.; U.S. Patent 3,567,710; March 2, 1971; assigned to Hoffman-La Roche, Inc.

General References
  1. Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. [PubMed:2883820 ]
  2. Vermeeren A: Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297-328. [PubMed:15089115 ]
  3. Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451 ]
  4. Rooke KC: The use of flurazepam (dalmane) as a substitute for barbiturates and methaqualone/diphenhydramine (mandrax) in general practice. J Int Med Res. 1976;4(5):355-9. [PubMed:18375 ]
  5. Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine]. Arch Fr Pediatr. 1977 Jan;34(1):74-89. [PubMed:851373 ]
  6. Link [Link]
External Links
ATC CodesN05CD01
AHFS Codes
  • 28:24.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (50.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9898
Caco-2 permeable+0.6115
P-glycoprotein substrateSubstrate0.8553
P-glycoprotein inhibitor IInhibitor0.9455
P-glycoprotein inhibitor IIInhibitor0.6624
Renal organic cation transporterInhibitor0.6523
CYP450 2C9 substrateNon-substrate0.7716
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7794
CYP450 1A2 substrateInhibitor0.5194
CYP450 2C9 inhibitorNon-inhibitor0.7112
CYP450 2D6 inhibitorNon-inhibitor0.5469
CYP450 2C19 inhibitorInhibitor0.5082
CYP450 3A4 inhibitorInhibitor0.6347
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6231
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7597
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5654 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9528
hERG inhibition (predictor II)Inhibitor0.7183
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Valeant pharmaceuticals international
  • Halsey drug co inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Superpharm corp
  • Usl pharma inc
  • Warner chilcott inc
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
CapsuleOral30 mg/1
CapsuleOral15 mg/1
CapsuleOral15 mg
CapsuleOral30 mg
TabletOral15 mg
TabletOral30 mg
Prices
Unit descriptionCostUnit
Dalmane 30 mg capsule2.01USD capsule
Dalmane 15 mg capsule1.79USD capsule
Flurazepam HCl 15 mg capsule0.43USD capsule
Flurazepam HCl 30 mg capsule0.4USD capsule
Flurazepam 30 mg capsule0.34USD capsule
Flurazepam 15 mg capsule0.28USD capsule
Apo-Flurazepam 30 mg Capsule0.1USD capsule
Apo-Flurazepam 15 mg Capsule0.08USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point190-220British Patent 1,040,548.
water solubility500 mg/mL (HCl salt)Not Available
logP3.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.01 mg/mLALOGPS
logP3.81ALOGPS
logP3.95ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)8.71ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area35.91 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity107.54 m3·mol-1ChemAxon
Polarizability41.22 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Halobenzene
  • Fluorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Aryl chloride
  • Tertiary carboxylic acid amide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Lactam
  • Ketimine
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Imine
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transmembrane signaling receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRQ
Uniprot ID:
Q9UN88
Molecular Weight:
72020.875 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Capello S, Henderson L, DeGrazia F, Liberato D, Garland W, Town C: The effect of the cytochrome P-450 suicide inactivator, 1-aminobenzotriazole, on the in vivo metabolism and pharmacologic activity of flurazepam. Drug Metab Dispos. 1990 Mar-Apr;18(2):190-6. [PubMed:1971572 ]
  2. Linder CD, Renaud NA, Hutzler JM: Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3. doi: 10.1124/dmd.108.024075. Epub 2008 Oct 20. [PubMed:18936109 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Capello S, Henderson L, DeGrazia F, Liberato D, Garland W, Town C: The effect of the cytochrome P-450 suicide inactivator, 1-aminobenzotriazole, on the in vivo metabolism and pharmacologic activity of flurazepam. Drug Metab Dispos. 1990 Mar-Apr;18(2):190-6. [PubMed:1971572 ]
  2. Linder CD, Renaud NA, Hutzler JM: Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3. doi: 10.1124/dmd.108.024075. Epub 2008 Oct 20. [PubMed:18936109 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Zolk O, Solbach TF, Konig J, Fromm MF: Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab Dispos. 2009 Jun;37(6):1312-8. doi: 10.1124/dmd.108.023762. Epub 2009 Feb 27. [PubMed:19251820 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23